With 0.86 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.22 million shares. During the session, the Diagnostics & Research company that operates in wider Healthcare sector, reached to the highest price of $0.419 whereas the lowest price it dropped to was $0.316. The 52-week range on ENZ shows that it touched its highest point at $1.16 and its lowest point at $0.25 during that stretch. It currently has a 1-year price target of $5.50. With its current market cap of 20.00 million, ENZ has annualized dividend of $0.10 while the current yield stands at 26.21%. ENZ paid its most recent dividend on 1731628800, while the ex-dividend date for that was 1731628800. Beta for the stock currently stands at 1.12.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ENZ was up-trending over the past week, with a rise of 14.22%, but this was down by -23.14% over a month. Three-month performance dropped to -45.47% while six-month performance fell -62.98%. The stock lost -63.94% in the past year, while it has lost -46.58% so far this year.
Float and Shares Shorts:
At present, 52.40 million ENZ shares are outstanding with a float of 37.75 million shares on hand for trading. On 2025-03-31, short shares totaled 0.36 million, which was 69.99999799999999 higher than short shares on 1740700800. In addition to Ms. Kara Cannon as the firm’s CEO & Director, Ms. Patricia Eckert CPA serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.34789002 of ENZ’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-01-31, ENZ reported revenue of $7334000.0 and operating income of -$1602000.0. The EBITDA in the recently reported quarter was -$1050000.0 and diluted EPS was -$0.03.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Based on analyst estimates, the high estimate for the next quarter is $0 and the low estimate is $0. The average estimate for the next quarter is thus $0.
